Abstract
Multiple sclerosis (MS) is a disorder of the central nervous system (CNS). It is characterized by episodic and progressive neurological dysfunction resulting from inflammatory and autoimmune reactions, myelin loss, conduction block, oligodendrocyte pathology, gliosis, and axonal loss in CNS. Recent years have witnessed advances in better understanding the immune pathogenesis of MS, prompted by animal models, human pathological observations and MRI studies. There have been significant changes in the therapeutic regimens in MS, with an emphasis on preventative treatment of an ongoing disease process. Agents in use and in the research pipeline have mechanisms that act on various antiinflammatory and immunomodulatory properties, including blocking leukocyte migration into CNS and targeting chemoattraction. In addition, recent studies on the neurodegenerative components of MS have directed therapeutic trials to neuroprotection and neurorestoration. In this paper, we summarize the current understanding of the mechanisms of approved pharmacological agents and review the putative mechanisms and status of some important agents in clinical phase two or three trials in MS.
Keywords: Multiple sclerosis, autoimmunity, therapy, clinical trials
Central Nervous System Agents in Medicinal Chemistry
Title: Advances in the Immune Pathogenesis and Treatment of Multiple Sclerosis
Volume: 9 Issue: 1
Author(s): DeRen Huang and Alexander Rae-Grant
Affiliation:
Keywords: Multiple sclerosis, autoimmunity, therapy, clinical trials
Abstract: Multiple sclerosis (MS) is a disorder of the central nervous system (CNS). It is characterized by episodic and progressive neurological dysfunction resulting from inflammatory and autoimmune reactions, myelin loss, conduction block, oligodendrocyte pathology, gliosis, and axonal loss in CNS. Recent years have witnessed advances in better understanding the immune pathogenesis of MS, prompted by animal models, human pathological observations and MRI studies. There have been significant changes in the therapeutic regimens in MS, with an emphasis on preventative treatment of an ongoing disease process. Agents in use and in the research pipeline have mechanisms that act on various antiinflammatory and immunomodulatory properties, including blocking leukocyte migration into CNS and targeting chemoattraction. In addition, recent studies on the neurodegenerative components of MS have directed therapeutic trials to neuroprotection and neurorestoration. In this paper, we summarize the current understanding of the mechanisms of approved pharmacological agents and review the putative mechanisms and status of some important agents in clinical phase two or three trials in MS.
Export Options
About this article
Cite this article as:
Huang DeRen and Rae-Grant Alexander, Advances in the Immune Pathogenesis and Treatment of Multiple Sclerosis, Central Nervous System Agents in Medicinal Chemistry 2009; 9 (1) . https://dx.doi.org/10.2174/187152409787601923
DOI https://dx.doi.org/10.2174/187152409787601923 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Molecular Targeting Agents in Renal Cell Carcinoma: Present Strategies and Future Perspectives
Current Pharmaceutical Design Safety of Systemic Biologic Agents in the Treatment of Non-malignant Skin Disorders
Current Drug Safety The Genetics of Small-Vessel Disease
Current Medicinal Chemistry Use of Kv1.3 Blockers for Inflammatory Skin Conditions
Current Medicinal Chemistry Impact of HIV on Regional & Cellular Organisation of the Brain
Current HIV Research Dysfunctions of the Diffusional Membrane Pathways Mediated Hemichannels in Inherited and Acquired Human Diseases
Current Vascular Pharmacology Emerging Therapeutic Approaches Multi-Targeting Receptor Tyrosine Kinases and G Protein-Coupled Receptors in Cardiovascular Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Toxicities of Immunosuppressive Treatment of Autoimmune Neurologic Diseases
Current Neuropharmacology Microbes, Immunity and Multiple Sclerosis
Current Immunology Reviews (Discontinued) HIV-Infected Patients and Liver Transplantation: Who, When and Why
Current HIV Research Modulatory Effect of Sinapic Acid in Toluene Induced Dementia of Leukoencephalopathy Type in Wistar Rats: a Biochemical Study
The Natural Products Journal Fluorinated Molecules as Drugs and Imaging Agents in the CNS
Current Topics in Medicinal Chemistry BACE1 Levels Correlate with Phospho-Tau Levels in Human Cerebrospinal Fluid
Current Alzheimer Research Regulation of Gait and Balance: The Underappreciated Role of Neuronal Nicotinic Receptor Agonists
Current Pharmaceutical Design Natural Bioactives as Potential Therapeutic Modalities Against NeuroAIDS
Current Topics in Medicinal Chemistry Update on the Use of Biologics in Vasculitides
Current Pharmaceutical Biotechnology An Update of the Published Reports on Biologics Use for Psoriasis and the Reimbursement Status in Asia-Pacific Region
Current Rheumatology Reviews Disease Progression in Children with Vertically-Acquired HIV Infection in Sub-Saharan Africa: Reviewing the Need for HIV Treatment
Current HIV Research Small Ruminant Lentiviruses and Human Immunodeficiency Virus: Cousins that Take a Long View
Current HIV Research Aging and DNA Methylation
Current Chemical Biology